Redhill Biopharma Ltd. (RDHL) - Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, filed on April 27, 2026, incorporates a press release announcing Redhill Biopharma's full-year 2025 financial results and operational highlights. The reporting period covers the 12 months ended December 31, 2025. A significant structural change occurred in October 2025 with the formation of Talicia Holdings Inc. (THI), a joint venture with Cumberland Pharmaceuticals. Consequently, Talicia commercial operations are classified as "discontinued operations" in the 2025 financial statements, with year-over-year comparisons presented on a "continuing operations" basis (non-Talicia activities).
Key Financial Metrics
| Metric | 2025 (USD) | 2024 (USD) |
|---|---|---|
| Revenues (Continuing) | $0.3 million | $0.0 million |
| Operating Loss (Continuing) | $(7.9) million | $(6.5) million |
| Net Loss from Continuing Operations | $(8.1) million | $0.4 million (Income) |
| Net Income from Discontinued Operations | $7.7 million | $(8.6) million (Loss) |
| Total Net Loss for the Year | $(0.4) million | $(8.3) million |
| Cash Balance (Dec 31, 2025) | $4.1 million | $4.6 million |
| Total Assets | $25.3 million | $18.0 million |
| Total Liabilities | $21.1 million | $22.7 million |
| Shareholders' Equity | $4.3 million | $(4.7) million (Deficiency) |
Cash Flow Highlights: Net cash used in operating activities was $9.7 million. Net cash provided by financing activities was $7.3 million, primarily from equity offerings and warrant exercises. Net cash provided by investing activities was $1.7 million, driven by proceeds from the joint venture investment.
Material Changes vs. Prior Period
- Revenue Shift: Continuing operations revenue increased from $0 to $0.3 million, driven by an upfront payment from the Hyloris license for RHB-102 (Bekinda). Talicia revenues are now reported under discontinued operations or as a share of joint venture results.
- Profitability: The company moved from a net income of $0.4 million in 2024 (continuing operations) to a net loss of $8.1 million in 2025. This reversal is primarily due to the absence of $6.8 million in financial income from the revaluation of financial instruments in 2024 and higher operating expenses in 2025.
- Balance Sheet Turnaround: The company transitioned from a capital deficiency of $4.7 million in 2024 to positive equity of $4.3 million in 2025. Total assets increased by $7.3 million, largely due to the $12.1 million investment in the THI joint venture.
- Expense Increases: R&D expenses rose to $2.0 million (from $1.6 million) due to clinical activities. G&A expenses increased to $6.2 million (from $4.9 million), primarily due to legal costs associated with the Kukbo litigation.
Outlook, Management Commentary, and Risks
Strategic Transactions:
- Talicia Partnership: Cumberland Pharmaceuticals invested $4 million for a 30% stake in THI. Redhill retains 70%. The partnership aims to drive Talicia growth, with Cumberland and Apotex planning to integrate Cumberland's U.S. branded business.
- RHB-102 (Bekinda) Licensing: Licensed to Hyloris for worldwide rights (excluding North America) for up to $60 million in milestones plus royalties. This targets GLP-1/GIP-associated GI side effects.
- Legal Victory: A $10.5 million judgment against Kukbo Co. Ltd. is final and eligible for enforcement, though collection remains subject to future realization and is not recognized in financial statements.
- Liquidity: A $10 million line of credit was established with Alumni Capital LP via an Any Market Purchase Agreement.
R&D Pipeline Progress:
- Opaganib: Advancing in oncology (prostate cancer, neuroblastoma, CLL, breast cancer) and metabolic diseases. A Phase 2 study with Bayer's darolutamide in prostate cancer is ongoing.
- RHB-204: Received positive FDA feedback on the pathway to approval for Crohn's disease. New collaborations signed for MAP detection diagnostics.
- RHB-102: Planning accelerated FDA 505(b)(2) submission for GLP-1 side effects.
Risks and Contingencies:
- Collection Risk: The $10.5 million Kukbo judgment is not recognized as an asset until collected.
- Regulatory Risk: Success of RHB-204 and RHB-102 depends on FDA approval and successful clinical trial outcomes.
- Market Risk: Dependence on the success of the Talicia joint venture and the commercialization of licensed assets.
- Listing Compliance: Risks regarding maintaining Nasdaq listing requirements, including minimum bid price.
Investor Verification Checklist
- Cash Runway: Verify the sustainability of the $4.1 million cash balance against the $9.7 million annual operating cash burn.
- Kukbo Collection: Monitor updates on the enforcement and actual collection of the $10.5 million court judgment.
- Talicia JV Performance: Track the financial performance of Talicia Holdings Inc. (THI) and the timing of Cumberland's remaining $2 million investment tranche.
- RHB-102 Milestones: Confirm the achievement of commercial targets required to trigger the $60 million in potential milestone payments from Hyloris.
- Regulatory Milestones: Watch for FDA feedback on the RHB-204 Crohn's disease pathway and the RHB-102 505(b)(2) submission status.